How does delgocitinib differ mechanistically from other topical therapies used for CHE?

Featuring Brad Glick, DO, MPH | AAD Board of DirectorsProgram Director, Dermatology Residency, Larkin Health System, Palm Springs CampusAssistant Clinical Professor of Dermatology, Herbert Wertheim College of MedicineMiami, Florida | Published August 08, 2025